Back to search

Switzerland· 55300004

Gencydo 1%, Nasenspray

A medicinal product containing citri limonis fructus recentis succus (citrus limon (l.) burm. f., fructus), cydoniae fructus recentis extractum aquosum (cydonia oblonga mill., fructus), registered in Switzerland by Weleda AG and dispensed under Swissmedic category D.

Cat D (Swissmedic)

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedGencydo 1%, NasensprayATC—REGISTER NO.55300004PACKS LISTED0CHECKEDSeptember 12, 2026

The record

At a glance

Swissmedic (Switzerland)
Active substance
citri limonis fructus recentis succus (Citrus limon (L.) Burm. f., fructus), cydoniae fructus recentis extractum aquosum (Cydonia oblonga MILL., fructus)
Manufacturer
Weleda AG
Country
Switzerland (CH)
ATC code
—
Swissmedic category
D
Reimbursed
No
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/efdafab2-f25d-4b0f-bff9-d9d92a1307d3
GET /v1/drugs/efdafab2-f25d-4b0f-bff9-d9d92a1307d3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{}

See everything about citri limonis fructus recentis succus (citrus limon (l.) burm. f., fructus), cydoniae fructus recentis extractum aquosum (cydonia oblonga mill., fructus).

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.